LIVE WEBINAR: Wednesday, October 22, 2025, 6:00 PM – 7:00 PM ET
Cancer Q&A: Understanding the Role and Reality of CAR (Chimeric Antigen Receptor) T-Cell Therapy for Non-Hodgkin Lymphoma
A Live Webinar for Patients, Developed in Partnership with CancerCare®
Event Details
Download Webinar Slides
Download Slides (PDF) Download Slides (PPT)
Faculty Comments Appendix
Download Slides (PDF) Download Slides (PPT)
Join us on Wednesday, October 22nd for this live webinar
6:00 PM – 7:00 PM eastern time
Webinar Description
This special webinar is designed to educate patients about CAR T-cell therapy for non-Hodgkin lymphoma. Participants will learn about what is important in a diagnosis of non-Hodgkin lymphoma, key factors in treatment decision-making and what side effects may be encountered. Led by nationally renowned medical oncologist Dr Neil Love, this medical webinar is designed to provide accessible information for patients and their friends or family members.Key Takeaways
• Understand how CAR T-cell therapy works and what the treatment experience is like for patients
• Learn about available CAR T-cell therapy options for non-Hodgkin lymphoma
• Know about potential side effects of CAR T-cell therapy and what is done to prevent and manage them
• Contribute to shared decision-making between patients and their healthcare providers
Faculty
Jeremy S Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Manali Kamdar, MD, MBBS
Associate Professor
Clinical Director of Lymphoma Services
Morton and Sandra Saffer Endowed Chair in Hematology Research
Division of Hematology, Hematologic Malignancies
University of Colorado Cancer Center
Aurora, Colorado
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
Agenda
Wednesday, October 22, 2025
6:00 PM – 7:00 PM eastern time
Topics to Be Discussed
- Similarities and Differences in the Structures of Available Chimeric Antigen Receptor (CAR) T-Cell Constructs
- Patient Characteristics That Influence Eligibility for CAR T-Cell Therapy
- Treatment Options for Patients Based on Non-Hodgkin Lymphoma Subtype
- Treatment Side Effects and How to Manage Them